To compare the effect of combined treatment with chloroquine and olopatadine eye drops with treatment with olopatadine eye drops alone in patients with allergic conjunctivitis
Phase 2
- Conditions
- Health Condition 1: H101- Acute atopic conjunctivitis
- Registration Number
- CTRI/2019/05/019304
- Lead Sponsor
- RP Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients attending the outpatient department with clinically diagnosed allergic eye disease based on signs (itching, watering) and symptoms (conjunctival hyperemia, palpebral hypertrophy) will participate in the study. No other methods of diagnosis will be considered besides clinical signs and symptoms.
Exclusion Criteria
1.Uveitis, conjunctivitis and other ocular pathologies
2.Bronchial asthma, eczema
3.History of dry eye, blepharitis, contact lens use
4.Receiving topical or systemic medications
5.History of sensitivity to any constituents of the eye drops
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in ocular symptoms including eye itching and rubbing <br/ ><br>Timepoint: 1 week, 4 weeks, 2 months, 3 months, 6 months, 9 months, 1 year
- Secondary Outcome Measures
Name Time Method Alterations in Inflammatory markers in tear film(Alpha- Antitrypsin, MMP9, IL-1, IL-8, IFN gamma)Timepoint: 4 weeks, 3 months, 6 months, 9 months, 1 year